Equities research analysts at Jefferies Group boosted their target price on shares of Bristol-Myers Squibb (NYSE:BMY) to $48.00 in a research note issued to investors on Wednesday, AnalystRatingsNetwork reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s price target suggests a potential downside of 12.30% from the stock’s previous close. Bristol-Myers Squibb Co (NYSE:BMY) shares after opening at $54.90 moved to $55.47 on last trade day and at the end of the day closed at $54.74. Company price to sales ratio in past twelve months was calculated as 5.51 and price to cash ratio as 19.96. Bristol-Myers Squibb Co (NYSE:BMY) showed a negative weekly performance of -0.91%.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) could soon be without the services of its billionaire chairman Philip Frost if reports appearing on the media are true. It is reported that the entrepreneur might leave the Israel-based TEVA before his current terms expires next year. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares advanced 0.62% in last trading session and ended the day on $50.22. TEVA return on equity ratio is recorded as 5.70% and its return on assets is 2.70%. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) yearly performance is 29.67%.
Horizon Pharma, Inc. (NASDAQ: HZNP) and Vidara Therapeutics International Ltd. (Vidara) announced they have entered into a definitive agreement under which Horizon Pharma will acquire Vidara through a reverse merger for stock and cash valued at approximately $660 million. Horizon Pharma plc will be the name of the resulting company. Horizon Pharma Inc (NASDAQ:HZNP) shares moved up 9.13% in last trading session and was closed at $16.02, while trading in range of $15.40-$18.30. Horizon Pharma Inc (NASDAQ:HZNP) year to date performance is 110.24%.
The Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Mar. 17 reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. The net loss attributable to common stockholders for the quarter and year ended December 31, 2013, was $15.5 million, or $0.07 per share, and $66.0 million, or $0.36 per share, as compared with a net loss attributable to common stockholders of $659,000, or $0.00 per share, and $19.7 million, or $0.14 per share, for the quarter and year ended December 31, 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) weekly performance is 8.83%. On last trading day company shares ended up $3.82. Inovio Pharmaceuticals Inc (NYSEMKT:INO) distance from 50-day simple moving average is 31.25%. Analysts mean target price for the company is $3.80.
Leave a Reply